Thallion http://www.thallion.com/ Thallion Pharmaceuticals Inc. is a biotechnology company focussed on developing new treatments for under-served markets in oncology and infectious disease. en-ca Copyright 2007 daily THALLION AND LFB REPORT POSITIVE TOP-LINE RESULTS FROM THE PHASE II SHIGATEC TRIAL AT ‘VTEC 2012’ http://www.thallion.com/en/news-events/press-release.php?id=125 Montreal, Canada and Les Ulis, France, May 9, 2012 - Thallion Pharmaceuticals Inc. (TSX: TLN) and LFB Biotechnologies announced that, earlier today, positive top-line results from the Phase II SHIGATEC trial evaluating the Company's Shigamabs® drug candidate as a treatment for Shiga toxin-producing E. coli [STEC] infection were presented at the 8th International Symposium on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli Infections (VTEC 2012) in Amsterdam, The Netherlands.  Based on core Phase II data, the study has met its primary endpoint of safety and tolerability in a STEC-infected pediatric population.  STEC infection remains a significant public health concern, as highlighted by last year's German outbreak in which over 4,000 infections and 50 deaths were reported.  There are presently no drugs approved for treating STEC infections or their associated medical complications.  Shigamabs® uses a proven anti-toxin approach to neutralize the two types of toxins secreted by pathogenic E. coli with the intent of preventing the incidence and/or reducing the severity of a life-threatening disease called hemolytic uremic syndrome (HUS).  An additional benefit of this anti-toxin approach is that it is bacterial strain independent.The randomized, double-blind, placebo-controlled Phase II SHIGATEC Trial enrolled 45 patients, aged six months to 18 years and testing positive for STEC infection, in two cohorts. The first cohort compared standard of care combined with a low dose of Shigamabs® (1 mg/kg/dose) versus standard of care with placebo. The second cohort compared standard of care combined with a high dose of Shigamabs® (3 mg/kg/dose) versus standard of care with placebo.  As expected from published epidemiology data, most patients (60%) enrolled in the study were under the age of 2. In the SHIGATEC trial, Shigamabs® appears to be well tolerated and no drug-related adverse events were observed. This is consistent with the safety profile determined in the four previous Phase I studies in healthy adult volunteers.  An independent data monitoring committee will conduct a thorough review of the core safety data and will continue to monitor safety throughout the one year extension phase of the study.  As expected, given the small size of the trial, there were no statistically significant trends in efficacy; however, data analysis is ongoing."As the SHIGATEC trial was our first study conducted in the at risk pediatric population, confirming safety was our primary objective", said Dr. Allan Mandelzys, Thallion's Chief Executive Officer. "Having achieved that, once the SHIGATEC trial data are fully analyzed, we plan on meeting with key regulators to present the results and obtain guidance on the next phase of clinical development."About Shigamabs®Shigamabs® consists of two monoclonal antibodies designed to bind specifically and exclusively to the Shiga toxin 1 and Shiga toxin 2 toxins secreted by Shiga toxin- producing E. coli bacteria. STEC infections are primarily foodborne bacterial infections that cause serious health complications, particularly in young children and the elderly, and affect approximately 314,000 people annually in the industrialized world. There are no approved products available for the treatment of STEC infections. The Shigamabs® antibodies, administered as a single intravenous infusion, bind to their respective toxin and neutralize them by forming a complex that is absorbed and destroyed by the liver and spleen. The dual antibody approach enables Shigamabs® to address STEC infections caused by E. coli secreting either Shiga toxin 1, Shiga toxin 2 or both Shiga toxins. Shigamabs® has obtained orphan drug designation both in the U.S. and in Europe.About Thallion Pharmaceuticals Inc.Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical programs include Shigamabs® and TLN-4601, a novel anti-cancer therapy. Shigamabs® is a dual antibody product being evaluated in a Phase II clinical trial for the treatment of Shiga toxin-producing E. coli bacterial infections. Additional information about Thallion can be obtained at www.thallion.com.About LFB LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely Hemostasis, Immunology and Intensive Care. The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide and is also among the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies. With its strong focus on research, the LFB Group is pursuing a growth strategy that seeks to extend its activities at the international level and develop innovative therapies. In 2010, the LFB Group reported total turnover of 411.6 million euros, up 9.6%, and invested 86.5 million euros in product development. The LFB Group markets its products in 20 countries around the world. Forward-Looking StatementsThis press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the determination of the level of the TLN-232 licensor's damages by the Arbitral Tribunal as part of the final award, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in Thallion's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.For further information contact:Company Contact  Michael Singer Chief Financial Officer Phone: (514) 940-3600Fax: (514) 336-2343 E-mail: info@thallion.com Internet: www.thallion.com Investor ContactStephen KilmerKilmer Lucas Inc.Office: (212) 618-6347stephen@kilmerlucas.comMedia ContactMedia Contact:Leonard ZehrKilmer Lucas Inc.Office: (416) 833-9317leonard@kilmerlucas.com Montreal, Canada and Les Ulis, France, May 9, 2012 - Thallion Pharmaceuticals Inc. (TSX: TLN) and LFB Biotechnologies announced that, earlier today, positive top-line results from the Phase II SHIGATEC trial evaluating the Company's Shigamabs® drug candidate as a treatment for Shiga toxin-producing E. coli [STEC] infection were presented at the 8th International Symposium on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli Infections (VTEC 2012) in Amsterdam, The Netherlands. 


Based on core Phase II data, the study has met its primary endpoint of safety and tolerability in a STEC-infected pediatric population. 


STEC infection remains a significant public health concern, as highlighted by last year's German outbreak in which over 4,000 infections and 50 deaths were reported.  There are presently no drugs approved for treating STEC infections or their associated medical complications.  Shigamabs® uses a proven anti-toxin approach to neutralize the two types of toxins secreted by pathogenic E. coli with the intent of preventing the incidence and/or reducing the severity of a life-threatening disease called hemolytic uremic syndrome (HUS).  An additional benefit of this anti-toxin approach is that it is bacterial strain independent.


The randomized, double-blind, placebo-controlled Phase II SHIGATEC Trial enrolled 45 patients, aged six months to 18 years and testing positive for STEC infection, in two cohorts. The first cohort compared standard of care combined with a low dose of Shigamabs® (1 mg/kg/dose) versus standard of care with placebo. The second cohort compared standard of care combined with a high dose of Shigamabs® (3 mg/kg/dose) versus standard of care with placebo.  As expected from published epidemiology data, most patients (60%) enrolled in the study were under the age of 2.


In the SHIGATEC trial, Shigamabs® appears to be well tolerated and no drug-related adverse events were observed. This is consistent with the safety profile determined in the four previous Phase I studies in healthy adult volunteers.  An independent data monitoring committee will conduct a thorough review of the core safety data and will continue to monitor safety throughout the one year extension phase of the study.  As expected, given the small size of the trial, there were no statistically significant trends in efficacy; however, data analysis is ongoing.


"As the SHIGATEC trial was our first study conducted in the at risk pediatric population, confirming safety was our primary objective", said Dr. Allan Mandelzys, Thallion's Chief Executive Officer. "Having achieved that, once the SHIGATEC trial data are fully analyzed, we plan on meeting with key regulators to present the results and obtain guidance on the next phase of clinical development."


About Shigamabs®
Shigamabs® consists of two monoclonal antibodies designed to bind specifically and exclusively to the Shiga toxin 1 and Shiga toxin 2 toxins secreted by Shiga toxin- producing E. coli bacteria. STEC infections are primarily foodborne bacterial infections that cause serious health complications, particularly in young children and the elderly, and affect approximately 314,000 people annually in the industrialized world. There are no approved products available for the treatment of STEC infections. The Shigamabs® antibodies, administered as a single intravenous infusion, bind to their respective toxin and neutralize them by forming a complex that is absorbed and destroyed by the liver and spleen. The dual antibody approach enables Shigamabs® to address STEC infections caused by E. coli secreting either Shiga toxin 1, Shiga toxin 2 or both Shiga toxins. Shigamabs® has obtained orphan drug designation both in the U.S. and in Europe.


About Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical programs include Shigamabs® and TLN-4601, a novel anti-cancer therapy. Shigamabs® is a dual antibody product being evaluated in a Phase II clinical trial for the treatment of Shiga toxin-producing E. coli bacterial infections. Additional information about Thallion can be obtained at www.thallion.com.


About LFB
LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely Hemostasis, Immunology and Intensive Care. The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide and is also among the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies. With its strong focus on research, the LFB Group is pursuing a growth strategy that seeks to extend its activities at the international level and develop innovative therapies. In 2010, the LFB Group reported total turnover of 411.6 million euros, up 9.6%, and invested 86.5 million euros in product development. The LFB Group markets its products in 20 countries around the world.


Forward-Looking Statements
This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the determination of the level of the TLN-232 licensor's damages by the Arbitral Tribunal as part of the final award, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in Thallion's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.


For further information contact:
Company Contact  
Michael Singer
Chief Financial Officer
Phone: (514) 940-3600
Fax: (514) 336-2343
E-mail: info@thallion.com
Internet: www.thallion.com

Investor Contact
Stephen Kilmer
Kilmer Lucas Inc.
Office: (212) 618-6347
stephen@kilmerlucas.com

Media Contact
Media Contact:
Leonard Zehr
Kilmer Lucas Inc.
Office: (416) 833-9317
leonard@kilmerlucas.com

]]> THALLION AND LFB REPORT POSITIVE TOP-LINE RESULTS FROM THE PHASE II SHIGATEC TRIAL AT ‘VTEC 2012’ 2012-05-09 07:18:11 THALLION ANNOUNCES 2012 FIRST QUARTER RESULTS AND PROVIDES SHIGAMABS UPDATE http://www.thallion.com/en/news-events/press-release.php?id=124 THALLION ANNOUNCES 2012 FIRST QUARTER RESULTS AND PROVIDES SHIGAMABS UPDATE 2012-04-24 16:53:55 THALLION ANNOUNCES 2011 YEAR END RESULTS http://www.thallion.com/en/news-events/press-release.php?id=123 THALLION ANNOUNCES 2011 YEAR END RESULTS 2012-02-22 15:58:04 THALLION AND LFB COMPLETE PATIENT ENROLLMENT OF PHASE II SHIGATEC TRIAL http://www.thallion.com/en/news-events/press-release.php?id=122 Montréal, Les Ulis, January 9, 2012 - Thallion Pharmaceuticals Inc. (TSX: TLN) and LFB Biotechnologies announced today that they have completed patient enrollment for the high dose cohort (3 mg/kg) of the Phase II SHIGATEC trial, evaluating Shigamabs® as a treatment for Shiga toxin-producing E. coli (STEC) infection. "The timely completion of patient recruitment and the two month patient follow up sets the stage for reporting top line SHIGATEC results early in the second quarter," said Dr. Allan Mandelzys, Thallion's Chief Executive Officer. "With the achievement of this significant milestone, we are now focused on moving forward with our anticipated Phase III clinical trial.""We remain excited about the potential Shigamabs® represents in delivering an important therapy to the thousands of people who suffer from this terrible and potentially life-threatening infection each year" said Guillaume Bologna, Executive Vice-President for Development Programs of LFB Biotechnologies. About the SHIGATEC TrialThe randomized, double-blind, placebo-controlled trial enrolled 45 patients, aged six months to 18 years testing positive for STEC infection, distributed in two cohorts. The first cohort compares standard of care combined with a low dose of Shigamabs® (1 mg/kg/dose) versus standard of care with placebo. The second cohort compares standard of care combined with a high dose of Shigamabs® (3 mg/kg/dose) versus standard of care with placebo. The primary endpoints for the Phase II trial are safety and tolerability. Secondary endpoints include pharmacokinetics and objective measures of efficacy using single and composite endpoints.About Shigamabs®Shigamabs® consists of two monoclonal antibodies designed to bind specifically and exclusively to the Shiga toxin 1 and Shiga toxin 2 toxins secreted by Shiga toxin- producing E. coli bacteria. STEC infections are primarily foodborne bacterial infections that cause serious health complications, particularly in young children and the elderly, and affect approximately 314,000 people annually in the industrialized world. There are no approved products available for the treatment of STEC infections. The Shigamabs® antibodies, administered as a single intravenous infusion, bind to their respective toxin and neutralize them by forming a complex that is absorbed and destroyed by the liver and spleen. The dual antibody approach enables Shigamabs® to address STEC infections caused by E. coli secreting either Shiga toxin 1, Shiga toxin 2 or both Shiga toxins. Shigamabs® has obtained orphan drug designation both in the U.S. and in Europe.About Thallion Pharmaceuticals Inc.Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical programs include Shigamabs® and TLN-4601, a novel anti-cancer therapy. Shigamabs® is a dual antibody product being evaluated in a Phase II clinical trial for the treatment of Shiga toxin-producing E. coli bacterial infections. Additional information about Thallion can be obtained at www.thallion.com.About LFB LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely Hemostasis, Immunology and Intensive Care. The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide and is also among the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies. With its strong focus on research, the LFB Group is pursuing a growth strategy that seeks to extend its activities at the international level and develop innovative therapies. In 2010, the LFB Group reported total turnover of 411.6 million euros, up 9.6%, and invested 86.5 million euros in product development. The LFB Group markets its products in 20 countries around the world. Forward-Looking StatementsThis press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the determination of the level of the TLN-232 licensor's damages by the Arbitral Tribunal as part of the final award, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in Thallion's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.For further information contact:Company Contact  Michael Singer Chief Financial Officer Phone: (514) 940-3600Fax: (514) 336-2343 E-mail: info@thallion.com Internet: www.thallion.com Investor ContactStephen KilmerKilmer Lucas Inc.Office: (212) 618-6347stephen@kilmerlucas.comMedia ContactMedia Contact:Leonard ZehrKilmer Lucas Inc.Office: (905) 690-2400 X41 Montréal, Les Ulis, January 9, 2012 - Thallion Pharmaceuticals Inc. (TSX: TLN) and LFB Biotechnologies announced today that they have completed patient enrollment for the high dose cohort (3 mg/kg) of the Phase II SHIGATEC trial, evaluating Shigamabs® as a treatment for Shiga toxin-producing E. coli (STEC) infection.


"The timely completion of patient recruitment and the two month patient follow up sets the stage for reporting top line SHIGATEC results early in the second quarter," said Dr. Allan Mandelzys, Thallion's Chief Executive Officer. "With the achievement of this significant milestone, we are now focused on moving forward with our anticipated Phase III clinical trial."
"We remain excited about the potential Shigamabs® represents in delivering an important therapy to the thousands of people who suffer from this terrible and potentially life-threatening infection each year" said Guillaume Bologna, Executive Vice-President for Development Programs of LFB Biotechnologies.


About the SHIGATEC Trial
The randomized, double-blind, placebo-controlled trial enrolled 45 patients, aged six months to 18 years testing positive for STEC infection, distributed in two cohorts. The first cohort compares standard of care combined with a low dose of Shigamabs® (1 mg/kg/dose) versus standard of care with placebo. The second cohort compares standard of care combined with a high dose of Shigamabs® (3 mg/kg/dose) versus standard of care with placebo. The primary endpoints for the Phase II trial are safety and tolerability. Secondary endpoints include pharmacokinetics and objective measures of efficacy using single and composite endpoints.


About Shigamabs®
Shigamabs® consists of two monoclonal antibodies designed to bind specifically and exclusively to the Shiga toxin 1 and Shiga toxin 2 toxins secreted by Shiga toxin- producing E. coli bacteria. STEC infections are primarily foodborne bacterial infections that cause serious health complications, particularly in young children and the elderly, and affect approximately 314,000 people annually in the industrialized world. There are no approved products available for the treatment of STEC infections. The Shigamabs® antibodies, administered as a single intravenous infusion, bind to their respective toxin and neutralize them by forming a complex that is absorbed and destroyed by the liver and spleen. The dual antibody approach enables Shigamabs® to address STEC infections caused by E. coli secreting either Shiga toxin 1, Shiga toxin 2 or both Shiga toxins. Shigamabs® has obtained orphan drug designation both in the U.S. and in Europe.


About Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical programs include Shigamabs® and TLN-4601, a novel anti-cancer therapy. Shigamabs® is a dual antibody product being evaluated in a Phase II clinical trial for the treatment of Shiga toxin-producing E. coli bacterial infections. Additional information about Thallion can be obtained at www.thallion.com.


About LFB
LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely Hemostasis, Immunology and Intensive Care. The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide and is also among the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies. With its strong focus on research, the LFB Group is pursuing a growth strategy that seeks to extend its activities at the international level and develop innovative therapies. In 2010, the LFB Group reported total turnover of 411.6 million euros, up 9.6%, and invested 86.5 million euros in product development. The LFB Group markets its products in 20 countries around the world.


Forward-Looking Statements
This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the determination of the level of the TLN-232 licensor's damages by the Arbitral Tribunal as part of the final award, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in Thallion's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

For further information contact:
Company Contact  
Michael Singer
Chief Financial Officer
Phone: (514) 940-3600
Fax: (514) 336-2343
E-mail: info@thallion.com
Internet: www.thallion.com

Investor Contact
Stephen Kilmer
Kilmer Lucas Inc.
Office: (212) 618-6347
stephen@kilmerlucas.com

Media Contact
Media Contact:
Leonard Zehr
Kilmer Lucas Inc.
Office: (905) 690-2400 X41

]]> THALLION AND LFB COMPLETE PATIENT ENROLLMENT OF PHASE II SHIGATEC TRIAL 2012-01-09 07:59:26 BLINDED RESULTS FROM LOW DOSE COHORT OF PHASE II SHIGATEC TRIAL PRESENTED AT IDSA ANNUAL MEETING http://www.thallion.com/en/news-events/press-release.php?id=121 Montreal, October 24, 2011 - Thallion Pharmaceuticals Inc. (TSX: TLN) announced that blinded results from the low dose cohort of its Phase II SHIGATEC study were presented at the 49th Infectious Disease Society of America ("IDSA") Annual Meeting in Boston, MA. The presentation entitled "SHIGATEC Trial: A Phase II Study Assessing Monoclonal Antibodies Against Shiga Toxin 1 and 2 in Shiga Toxin-producing E. coli-infected Children" reported on a total of 22 patients (out of 305 patients screened) that were enrolled in the low dose cohort.  Approximately two-thirds of the enrolled patients were less than four years old.   This was the first time Shigamabs® was assessed in a Shiga toxin-producing E. coli (STEC)-infected pediatric population and the presentation concluded that the treatment was safe and well tolerated. The majority of the infections were attributed to non-O157 E. coli strains, with a predominance of Shiga toxin 2 producers.   "We continue to be encouraged by the consistency of the Shigamabs® safety results across studies," said Dr. Allan Mandelzys, Thallion's Chief Executive Officer.  "Earlier this year, based on a planned safety analysis, the Independent Data Monitoring Committee for the SHIGATEC trial recommended that the study continue as per the protocol." Enrollment in the high dose cohort is ongoing and Thallion expects to present the unblinded data at a future scientific conference.For further detail, please visit the Company's website at www.thallion.comAbout the SHIGATEC TrialThe randomized, double-blind, placebo-controlled trial will enroll 42 patients, aged six months to 18 years testing positive for STEC infection, distributed in two cohorts. The first cohort compares standard of care combined with a single low dose of Shigamabs® (1 mg/kg) versus standard of care with placebo. The second cohort will compare standard of care combined with a single high dose of Shigamabs® (3 mg/kg) versus standard of care with placebo.  The primary endpoints for the Phase II trial are safety and tolerability. Secondary endpoints include pharmacokinetics and objective measures of efficacy using single and composite endpoints. About Shigamabs®Shigamabs® consists of two monoclonal antibodies designed to bind specifically and exclusively to the Shiga toxin 1 and Shiga toxin 2 toxins secreted by Shiga toxin- producing E. coli bacteria. STEC infections are primarily foodborne bacterial infections that cause serious health complications, particularly in young children and the elderly, and affect approximately 314,000 people annually in the industrialized world. There are no approved products available for the treatment of STEC infections. The Shigamabs® antibodies, administered as a single intravenous infusion, bind to their respective toxin and neutralize them by forming a complex that is absorbed and destroyed by the liver and spleen. The dual antibody approach enables Shigamabs® to address STEC infections caused by E. coli secreting either Shiga toxin 1, Shiga toxin 2 or both Shiga toxins. Shigamabs® has obtained orphan drug designation both in the U.S. and in Europe. About Thallion Pharmaceuticals Inc.Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical programs include Shigamabs® and TLN-4601, a novel anti-cancer therapy. Shigamabs® is a dual antibody product being evaluated in a Phase II clinical trial for the treatment of Shiga toxin-producing E. coli bacterial infections. Additional information about Thallion can be obtained at www.thallion.com. Forward-Looking StatementsThis press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the determination of the level of the TLN-232 licensor's damages by the Arbitral Tribunal as part of the final award, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in Thallion's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.For further information contact:Company Contact  Michael Singer Chief Financial Officer Phone: (514) 940-3600Fax: (514) 228-3622 E-mail: info@thallion.com Internet: www.thallion.com Investor ContactStephen KilmerKilmer Lucas Inc.Office: (212) 618-6347stephen@kilmerlucas.comMedia ContactMedia Contact:Leonard ZehrKilmer Lucas Inc.Office: (905) 486-1158len@kilmerlucas.com    Montreal, October 24, 2011 - Thallion Pharmaceuticals Inc. (TSX: TLN) announced that blinded results from the low dose cohort of its Phase II SHIGATEC study were presented at the 49th Infectious Disease Society of America ("IDSA") Annual Meeting in Boston, MA.
The presentation entitled "SHIGATEC Trial: A Phase II Study Assessing Monoclonal Antibodies Against Shiga Toxin 1 and 2 in Shiga Toxin-producing E. coli-infected Children" reported on a total of 22 patients (out of 305 patients screened) that were enrolled in the low dose cohort.  Approximately two-thirds of the enrolled patients were less than four years old.  
This was the first time Shigamabs® was assessed in a Shiga toxin-producing E. coli (STEC)-infected pediatric population and the presentation concluded that the treatment was safe and well tolerated. The majority of the infections were attributed to non-O157 E. coli strains, with a predominance of Shiga toxin 2 producers.  
"We continue to be encouraged by the consistency of the Shigamabs® safety results across studies," said Dr. Allan Mandelzys, Thallion's Chief Executive Officer.  "Earlier this year, based on a planned safety analysis, the Independent Data Monitoring Committee for the SHIGATEC trial recommended that the study continue as per the protocol."
Enrollment in the high dose cohort is ongoing and Thallion expects to present the unblinded data at a future scientific conference.
For further detail, please visit the Company's website at www.thallion.com


About the SHIGATEC Trial
The randomized, double-blind, placebo-controlled trial will enroll 42 patients, aged six months to 18 years testing positive for STEC infection, distributed in two cohorts. The first cohort compares standard of care combined with a single low dose of Shigamabs® (1 mg/kg) versus standard of care with placebo. The second cohort will compare standard of care combined with a single high dose of Shigamabs® (3 mg/kg) versus standard of care with placebo.  The primary endpoints for the Phase II trial are safety and tolerability. Secondary endpoints include pharmacokinetics and objective measures of efficacy using single and composite endpoints.
 

About Shigamabs®
Shigamabs® consists of two monoclonal antibodies designed to bind specifically and exclusively to the Shiga toxin 1 and Shiga toxin 2 toxins secreted by Shiga toxin- producing E. coli bacteria. STEC infections are primarily foodborne bacterial infections that cause serious health complications, particularly in young children and the elderly, and affect approximately 314,000 people annually in the industrialized world. There are no approved products available for the treatment of STEC infections. The Shigamabs® antibodies, administered as a single intravenous infusion, bind to their respective toxin and neutralize them by forming a complex that is absorbed and destroyed by the liver and spleen. The dual antibody approach enables Shigamabs® to address STEC infections caused by E. coli secreting either Shiga toxin 1, Shiga toxin 2 or both Shiga toxins. Shigamabs® has obtained orphan drug designation both in the U.S. and in Europe.
 

About Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical programs include Shigamabs® and TLN-4601, a novel anti-cancer therapy. Shigamabs® is a dual antibody product being evaluated in a Phase II clinical trial for the treatment of Shiga toxin-producing E. coli bacterial infections. Additional information about Thallion can be obtained at www.thallion.com.
 

Forward-Looking Statements
This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the determination of the level of the TLN-232 licensor's damages by the Arbitral Tribunal as part of the final award, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in Thallion's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.


For further information contact:
Company Contact  
Michael Singer
Chief Financial Officer
Phone: (514) 940-3600
Fax: (514) 228-3622
E-mail: info@thallion.com
Internet: www.thallion.com

Investor Contact
Stephen Kilmer
Kilmer Lucas Inc.
Office: (212) 618-6347
stephen@kilmerlucas.com

Media Contact
Media Contact:
Leonard Zehr
Kilmer Lucas Inc.
Office: (905) 486-1158
len@kilmerlucas.com 

 

]]> BLINDED RESULTS FROM LOW DOSE COHORT OF PHASE II SHIGATEC TRIAL PRESENTED AT IDSA ANNUAL MEETING 2011-10-24 16:21:32 THALLION ANNOUNCES 2011 THIRD QUARTER RESULTS http://www.thallion.com/en/news-events/press-release.php?id=120 THALLION ANNOUNCES 2011 THIRD QUARTER RESULTS 2011-10-11 16:40:55 THALLION RESUMING PATIENT RECRUITMENT IN PHASE II SHIGATEC TRIAL http://www.thallion.com/en/news-events/press-release.php?id=119 THALLION RESUMING PATIENT RECRUITMENT IN PHASE II SHIGATEC TRIAL 2011-10-11 16:35:58 THALLION PROVIDES UPDATE ON PHASE II SHIGATEC TRIAL http://www.thallion.com/en/news-events/press-release.php?id=118 Montre?al, September 13, 2011 - Thallion Pharmaceuticals Inc. (TSX: TLN) announced today its intention to resume patient recruitment in its Phase II SHIGATEC study during October 2011, just before the upcoming high season for Shiga toxin-producing E. coli bacteria ("STEC") infections in South America.On July 13, 2011, the Company announced that due to a preliminary product out-of-specification ("OOS") finding observed during routine stability testing of its anti-Stx1 monoclonal antibody, it decided to temporarily suspend screening and enrollment in the SHIGATEC study as a precautionary measure pending a more comprehensive assessment of the situation.Over the course of the past several weeks, Thallion, in close collaboration with its development partner LFB Biotechnologies ("LFB"), has completed an in-depth analysis of the product OOS finding. The results of this examination provide support for the continued use of the existing clinical product. The Company has nevertheless decided to wait for the results from one additional stability time point in early October before re-activating the study. In parallel, the Company and LFB have committed to the manufacturing of a new lot of anti-Stx1 clinical material to provide further assurance for the timely completion of the trial. This new lot is expected to become available for use in the clinical study, if needed, in December.     "Whether the temporary suspension is lifted in October, as currently anticipated, or we elect to wait until the new lot of clinical material becomes available, we are confident that we will complete the SHIGATEC Phase II trial during this upcoming  high season for STEC infections," said Dr. Allan Mandelzys, Thallion's Chief Executive Officer.  "Accordingly, this temporary suspension should not adversely impact our overall clinical development timelines in a material way." About the SHIGATEC TrialThe randomized, double-blind, placebo-controlled trial will enroll 42 patients, aged six months to 18 years testing positive for STEC infection, distributed in two cohorts. The first cohort compares standard of care combined with a low dose of Shigamabs® (1 mg/kg/dose) versus standard of care with placebo. The second cohort will compare standard of care combined with a high dose of Shigamabs® (3 mg/kg/dose) versus standard of care with placebo.  The primary endpoints for the Phase II trial are safety and tolerability. Secondary endpoints include pharmacokinetics and objective measures of efficacy using single and composite endpoints.About Shigamabs®Shigamabs® consists of two monoclonal antibodies designed to bind specifically and exclusively to the Shiga toxin 1 and Shiga toxin 2 toxins secreted by Shiga toxin- producing E. coli bacteria. STEC infections are primarily foodborne bacterial infections that cause serious health complications, particularly in young children and the elderly, and affect approximately 314,000 people annually in the industrialized world. There are no approved products available for the treatment of STEC infections. The Shigamabs® antibodies, administered as a single intravenous infusion, bind to their respective toxin and neutralize them by forming a complex that is absorbed and destroyed by the liver and spleen. The dual antibody approach enables Shigamabs® to address STEC infections caused by E. coli secreting either Shiga toxin 1, Shiga toxin 2 or both Shiga toxins. Shigamabs® has obtained orphan drug designation both in the U.S. and in Europe.About Thallion Pharmaceuticals Inc.Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical programs include Shigamabs® and TLN-4601, a novel anti-cancer therapy. Shigamabs® is a dual antibody product being evaluated in a Phase II clinical trial for the treatment of Shiga toxin-producing E. coli bacterial infections. Additional information about Thallion can be obtained at www.thallion.com.Forward-Looking StatementsThis press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in Thallion's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.For further information contact:Company Contact      Michael Singer Chief Financial Officer Phone: (514) 940-3600Fax: (514) 228-3622 E-mail: info@thallion.com Internet: http://www.thallion.com/  Investor ContactStephen KilmerKilmer Lucas Inc.Office: (212) 618-6347stephen@kilmerlucas.com Media ContactMedia Contact:Leonard ZehrKilmer Lucas Inc.Office: (905) 690-2400 X41len@kilmerlucas.com  Montre?al, September 13, 2011 - Thallion Pharmaceuticals Inc. (TSX: TLN) announced today its intention to resume patient recruitment in its Phase II SHIGATEC study during October 2011, just before the upcoming high season for Shiga toxin-producing E. coli bacteria ("STEC") infections in South America.

On July 13, 2011, the Company announced that due to a preliminary product out-of-specification ("OOS") finding observed during routine stability testing of its anti-Stx1 monoclonal antibody, it decided to temporarily suspend screening and enrollment in the SHIGATEC study as a precautionary measure pending a more comprehensive assessment of the situation.

Over the course of the past several weeks, Thallion, in close collaboration with its development partner LFB Biotechnologies ("LFB"), has completed an in-depth analysis of the product OOS finding. The results of this examination provide support for the continued use of the existing clinical product. The Company has nevertheless decided to wait for the results from one additional stability time point in early October before re-activating the study. In parallel, the Company and LFB have committed to the manufacturing of a new lot of anti-Stx1 clinical material to provide further assurance for the timely completion of the trial. This new lot is expected to become available for use in the clinical study, if needed, in December.   

 "Whether the temporary suspension is lifted in October, as currently anticipated, or we elect to wait until the new lot of clinical material becomes available, we are confident that we will complete the SHIGATEC Phase II trial during this upcoming  high season for STEC infections," said Dr. Allan Mandelzys, Thallion's Chief Executive Officer.  "Accordingly, this temporary suspension should not adversely impact our overall clinical development timelines in a material way."

About the SHIGATEC Trial

The randomized, double-blind, placebo-controlled trial will enroll 42 patients, aged six months to 18 years testing positive for STEC infection, distributed in two cohorts. The first cohort compares standard of care combined with a low dose of Shigamabs® (1 mg/kg/dose) versus standard of care with placebo. The second cohort will compare standard of care combined with a high dose of Shigamabs® (3 mg/kg/dose) versus standard of care with placebo.  The primary endpoints for the Phase II trial are safety and tolerability. Secondary endpoints include pharmacokinetics and objective measures of efficacy using single and composite endpoints.

About Shigamabs®

Shigamabs® consists of two monoclonal antibodies designed to bind specifically and exclusively to the Shiga toxin 1 and Shiga toxin 2 toxins secreted by Shiga toxin- producing E. coli bacteria. STEC infections are primarily foodborne bacterial infections that cause serious health complications, particularly in young children and the elderly, and affect approximately 314,000 people annually in the industrialized world. There are no approved products available for the treatment of STEC infections. The Shigamabs® antibodies, administered as a single intravenous infusion, bind to their respective toxin and neutralize them by forming a complex that is absorbed and destroyed by the liver and spleen. The dual antibody approach enables Shigamabs® to address STEC infections caused by E. coli secreting either Shiga toxin 1, Shiga toxin 2 or both Shiga toxins. Shigamabs® has obtained orphan drug designation both in the U.S. and in Europe.

About Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical programs include Shigamabs® and TLN-4601, a novel anti-cancer therapy. Shigamabs® is a dual antibody product being evaluated in a Phase II clinical trial for the treatment of Shiga toxin-producing E. coli bacterial infections. Additional information about Thallion can be obtained at www.thallion.com.

Forward-Looking Statements

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in Thallion's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

For further information contact:

Company Contact     

Michael Singer

Chief Financial Officer

Phone: (514) 940-3600

Fax: (514) 228-3622

E-mail: info@thallion.com

Internet: http://www.thallion.com/

 

Investor Contact

Stephen Kilmer

Kilmer Lucas Inc.

Office: (212) 618-6347

stephen@kilmerlucas.com

 

Media Contact

Media Contact:

Leonard Zehr

Kilmer Lucas Inc.

Office: (905) 690-2400 X41

len@kilmerlucas.com 

]]> THALLION PROVIDES UPDATE ON PHASE II SHIGATEC TRIAL 2011-09-13 08:24:40 THALLION ANNOUNCES 2011 SECOND QUARTER RESULTS http://www.thallion.com/en/news-events/press-release.php?id=117 THALLION ANNOUNCES 2011 SECOND QUARTER RESULTS 2011-07-13 17:01:29 THALLION PROVIDES UPDATE ON PHASE II SHIGATEC TRIAL http://www.thallion.com/en/news-events/press-release.php?id=115 Montreal, July, 13, 2011 - Thallion Pharmaceuticals Inc. (TSX: TLN) announced today that it has temporarily suspended the screening and enrollment of the high dose cohort of its Phase II SHIGATEC study as a precautionary measure due to a preliminary product out-of-specification ("OOS") finding observed during routine stability testing of its anti-Stx1 monoclonal antibody."This voluntary action reflects our uncompromising view towards the safety and care of our patients," commented Dr. Allan Mandelzys, Chief Executive Officer of Thallion.  "Until we have more complete data to fully assess the situation, we determined that temporarily suspending enrollment is the appropriate and most conservative decision."The company, together with its development partner LFB Biotechnologies, is conducting a thorough analysis to better understand the nature of this product OOS finding over the coming weeks and will communicate the results of its assessment promptly. Potential outcomes could range from removing the temporary suspension and continuing the study with the current clinical material or maintaining the enrollment suspension until a new lot of clinical material is manufactured. About the SHIGATEC TrialThe randomized, double-blind, placebo-controlled trial will enroll 42 patients, aged six months to 18 years testing positive for STEC infection, distributed in two cohorts. The first cohort compares standard of care combined with a low dose of  Shigamabs® (1 mg/kg/dose) versus standard of care with placebo. The second cohort will compare standard of care combined with a high dose of Shigamabs® (3 mg/kg/dose) versus standard of care with placebo.  The primary endpoints for the Phase II trial are safety and tolerability. Secondary endpoints include pharmacokinetics and objective measures of efficacy using single and composite endpoints.About Shigamabs®Shigamabs® consists of two monoclonal antibodies designed to bind specifically and exclusively to the Shiga toxin 1 and Shiga toxin 2 toxins secreted by Shiga toxin- producing E. coli bacteria. STEC infections are primarily foodborne bacterial infections that cause serious health complications, particularly in young children and the elderly, and affect approximately 314,000 people annually in the industrialized world. There are no approved products available for the treatment of STEC infections. The Shigamabs® antibodies, administered as a single intravenous injection, bind to their respective toxin and neutralize them by forming a complex that is absorbed and destroyed by the liver and spleen. The dual antibody approach enables Shigamabs® to address STEC infections caused by E. coli secreting either Shiga toxin 1, Shiga toxin 2 or both Shiga toxins. Shigamabs® has obtained orphan drug designation both in the U.S. and in Europe.About Thallion Pharmaceuticals Inc.Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical programs include Shigamabs® and TLN-4601, a novel anti-cancer therapy. Shigamabs® is a dual antibody product being evaluated in a Phase II clinical trial for the treatment of Shiga toxin-producing E. coli bacterial infections. Additional information about Thallion can be obtained at www.thallion.com.Forward-Looking StatementsThis press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the determination of the level of the TLN-232 licensor's damages by the Arbitral Tribunal as part of the final award, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in Thallion's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.For further information contact:Company Contact Michael Singer Chief Financial Officer Phone: (514) 940-3600Fax: (514) 228-3622 E-mail: info@thallion.com Internet: www.thallion.com Investor ContactStephen KilmerKilmer Lucas Inc.Office: (212) 618-6347stephen@kilmerlucas.comMedia ContactMedia Contact:Leonard ZehrKilmer Lucas Inc.Office: (905) 690-2400 X41len@kilmerlucas.com   Montreal, July, 13, 2011 - Thallion Pharmaceuticals Inc. (TSX: TLN) announced today that it has temporarily suspended the screening and enrollment of the high dose cohort of its Phase II SHIGATEC study as a precautionary measure due to a preliminary product out-of-specification ("OOS") finding observed during routine stability testing of its anti-Stx1 monoclonal antibody.

"This voluntary action reflects our uncompromising view towards the safety and care of our patients," commented Dr. Allan Mandelzys, Chief Executive Officer of Thallion.  "Until we have more complete data to fully assess the situation, we determined that temporarily suspending enrollment is the appropriate and most conservative decision."
The company, together with its development partner LFB Biotechnologies, is conducting a thorough analysis to better understand the nature of this product OOS finding over the coming weeks and will communicate the results of its assessment promptly. Potential outcomes could range from removing the temporary suspension and continuing the study with the current clinical material or maintaining the enrollment suspension until a new lot of clinical material is manufactured. 

About the SHIGATEC Trial
The randomized, double-blind, placebo-controlled trial will enroll 42 patients, aged six months to 18 years testing positive for STEC infection, distributed in two cohorts. The first cohort compares standard of care combined with a low dose of  Shigamabs® (1 mg/kg/dose) versus standard of care with placebo. The second cohort will compare standard of care combined with a high dose of Shigamabs® (3 mg/kg/dose) versus standard of care with placebo.  The primary endpoints for the Phase II trial are safety and tolerability. Secondary endpoints include pharmacokinetics and objective measures of efficacy using single and composite endpoints.

About Shigamabs®
Shigamabs® consists of two monoclonal antibodies designed to bind specifically and exclusively to the Shiga toxin 1 and Shiga toxin 2 toxins secreted by Shiga toxin- producing E. coli bacteria. STEC infections are primarily foodborne bacterial infections that cause serious health complications, particularly in young children and the elderly, and affect approximately 314,000 people annually in the industrialized world. There are no approved products available for the treatment of STEC infections. The Shigamabs® antibodies, administered as a single intravenous injection, bind to their respective toxin and neutralize them by forming a complex that is absorbed and destroyed by the liver and spleen. The dual antibody approach enables Shigamabs® to address STEC infections caused by E. coli secreting either Shiga toxin 1, Shiga toxin 2 or both Shiga toxins. Shigamabs® has obtained orphan drug designation both in the U.S. and in Europe.
About Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical programs include Shigamabs® and TLN-4601, a novel anti-cancer therapy. Shigamabs® is a dual antibody product being evaluated in a Phase II clinical trial for the treatment of Shiga toxin-producing E. coli bacterial infections. Additional information about Thallion can be obtained at www.thallion.com.

Forward-Looking Statements
This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the determination of the level of the TLN-232 licensor's damages by the Arbitral Tribunal as part of the final award, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in Thallion's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.
For further information contact:

Company Contact
Michael Singer 
Chief Financial Officer 
Phone: (514) 940-3600
Fax: (514) 228-3622 
E-mail: info@thallion.com 
Internet: www.thallion.com 

Investor Contact
Stephen Kilmer
Kilmer Lucas Inc.
Office: (212) 618-6347
stephen@kilmerlucas.com

Media Contact
Media Contact:
Leonard Zehr
Kilmer Lucas Inc.
Office: (905) 690-2400 X41
len@kilmerlucas.com  

]]> THALLION PROVIDES UPDATE ON PHASE II SHIGATEC TRIAL 2011-07-13 08:18:47